Premium
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes
Author(s) -
Buch H. N.,
Baskar V.,
Barton D. M.,
Kamalakannan D.,
Akarca C.,
Singh B. M.
Publication year - 2002
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1046/j.1464-5491.2002.00734.x
Subject(s) - medicine , rosiglitazone , insulin , thiazolidinedione , type 2 diabetes , diabetes mellitus , endocrinology , weight loss , body mass index , obesity
Aims To evaluate the influence of addition of rosiglitazone to insulin therapy over a 24‐week period in massively obese patients with poorly controlled Type 2 diabetes taking large doses of insulin. Methods Eight massively obese patients (median body mass index (BMI) 42 kg/m 2 ) with Type 2 diabetes who were on large doses of insulin (median daily dose of 204 U) and/or had poor glycaemic control (median HbA 1c of 8.1% (upper limit for normal 5.5%)) were treated over a 24‐week period with the combination of insulin and maximum doses of rosiglitazone. Outcomes monitored were changes in weight, BMI, HbA 1c , dose of insulin and development of side‐effects. Results At the end of 24 weeks there was a median weight gain of 3 kg ( P < 0.01), a fall in median HbA 1c from 8.1% to 6.7% (16% reduction from baseline) ( P < 0.01) and a reduction in median insulin dose from 204 U/day to 159 U/day ( P < 0.01) (23% reduction from baseline). Peripheral oedema was the only significant side‐effect and was seen in five patients. Conclusions Combination of insulin and rosiglitazone is effective in massively obese patients with Type 2 diabetes, though there is a high incidence of peripheral oedema.